Valeant Hires Morgan Stanley to Sell Dermatology AssetsBy
Sale of Valeant’s Obagi, Solta could fetch up to $500 million
Process to sell assets set to kick off as early as this week
Valeant Pharmaceuticals International Inc. is working with advisers at Morgan Stanley as it weighs the sale of dermatology units Obagi Medical Products and Solta Medical to raise cash to reduce debt, according to people familiar with the matter.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.